Boston Scientific Corporation $BSX Stake Raised by Graham Capital Management L.P.

Key Points

• Graham Capital Management L.P. significantly increased its stake in Boston Scientific Corporation by 2,036.7% in the first quarter, owning 55,788 shares worth approximately $5.63 million.
• Several institutional investors, including Vanguard Group and Goldman Sachs, have also raised their positions in Boston Scientific, with institutional ownership now at 89.07% of the stock.
• Boston Scientific reported a quarterly revenue of $5.06 billion, surpassing analysts' expectations, and set its Q3 2025 EPS guidance between 0.700 and 0.720.

Graham Capital Management L.P. boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 2,036.7% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,788 shares of the medical equipment provider's stock after acquiring an additional 53,177 shares during the period. Graham Capital Management L.P.'s holdings in Boston Scientific were worth $5,628,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Armistice Capital LLC bought a new position in Boston Scientific in the first quarter worth about $5,020,000. Quarry LP lifted its holdings in Boston Scientific by 539.1% in the first quarter. Quarry LP now owns 1,732 shares of the medical equipment provider's stock worth $175,000 after acquiring an additional 1,461 shares during the last quarter. Saudi Central Bank bought a new position in Boston Scientific in the first quarter worth about $59,000. Baird Financial Group Inc. lifted its holdings in Boston Scientific by 6.1% in the first quarter. Baird Financial Group Inc. now owns 241,117 shares of the medical equipment provider's stock worth $24,324,000 after acquiring an additional 13,819 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. lifted its holdings in Boston Scientific by 2.9% in the first quarter. Pinnacle Wealth Planning Services Inc. now owns 6,436 shares of the medical equipment provider's stock worth $649,000 after acquiring an additional 180 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Leerink Partners assumed coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price on the stock. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Truist Financial lifted their price target on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Morgan Stanley lifted their price target on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Finally, Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Trading Down 0.2%

Shares of NYSE:BSX traded down $0.17 during midday trading on Thursday, reaching $107.36. The company had a trading volume of 7,354,441 shares, compared to its average volume of 7,484,820. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1-year low of $80.50 and a 1-year high of $108.94. The firm has a market cap of $159.09 billion, a price-to-earnings ratio of 63.91, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company has a fifty day simple moving average of $104.71 and a two-hundred day simple moving average of $102.18.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the company posted $0.62 EPS. Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.